MB
ALXO icon

MPM BioImpact’s ALX Oncology ALXO Stock Holding History

MPM BioImpact’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-550,000
Closed -$343K – 45
2025
Q1 		$343K Sell
550,000
-841,434
-60% -$1.01M 0.06% 43
2024
Q4 		$2.32M Sell
1,391,434
-1,018,428
-42% -$1.57M 0.33% 46
2024
Q3 		$4.39M Buy
2,409,862
+228,998
+11% +$851K 0.66% 39
2024
Q2 		$13.2M Buy
2,180,864
+912,393
+72% +$11.2M 2.04% 16
2024
Q1 		$14.1M Buy
1,268,471
+3,712
+0.3% +$52.1K 2.27% 15
2023
Q4 		$18.8M Buy
+1,264,759
New +$12M 4.41% 6

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

MPM BioImpact's ALXO Position: Q2 2025 in Review

MPM BioImpact sold out of ALX Oncology (ALXO) in Q2 2025, closing a stake of 550,000 shares — an estimated $343K sold.

MPM BioImpact first reported a position in ALXO in Q4 2023 and held it in 6 quarters. The position peaked at $18.8M in Q4 2023. 61 funds tracked by Wall St. Rank hold ALXO as of Q2 2025.

  • MPM BioImpact reported no remaining ALX Oncology position as of Q2 2025 after selling out during the quarter.
  • MPM BioImpact sold 550,000 ALX Oncology shares in Q2 2025, an estimated $343K.
  • MPM BioImpact first reported a position in ALX Oncology in Q4 2023 and held it in 6 quarters.
  • MPM BioImpact's ALX Oncology position peaked at $18.8M in Q4 2023.
  • 61 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2025.

Based on MPM BioImpact's 13F filing for Q2 2025, filed 14 Aug 2025.